Vnitr Lek 2008, 54(2):169-177

Dyslipidaemia inducted by antiretroviral agents

S. Snopková1,*, K. Povolná1, P. Husa1, J. Jarkovský2, T. Pavlík2
1 Klinika infekčních chorob Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Petr Husa, CSc.
2 Institut biostatistiky a analýz Masarykovy univerzity Brno, ředitel doc. RNDr. Ladislav Dušek, Dr.

The clinical course of HIV/AIDS has been substantially modified by up-to date therapy in the recent years. The progress of the disorder has changed - today it is a chronic disease of many years course. Already in 1997 and 1998 it turned out that adverse metabolic changes which significantly affect the subsequent progress of the disease were produced by long-term HAART (highly active antiretroviral therapy). Gradually, more and more anthropometric, metabolic and coagulation changes are detected, closely resembling the changes seen in the metabolic syndrome, well known from cardiology and internal medicine - dyslipoproteinaemia, insulin resistance, abdominal obesity and so on. A combination of these disorders is clinically significant due to their role in the development of atherosclerosis and their, by no means negligible, involvement in the onset of ischaemic heart disease. In view of the much lower average age of HIV-positive individuals the earlier mentioned complications should be expected in much lower age categories than with HIV-negative individuals. Plasma lipid fractions (total cholesterol, triglycerides, LDL-cholesterol, HDL-cholesterol, apoA-I, apoB, LDL/HDL, apoA-I/apoB) have been investigated in 69 HIV infected subjects and the changes of these parameteres in the course of progression of HIV/AIDS due to cumulative time of exposure to HAART were explored. Significant increase of the level of proatherogenic plasma lipid fractions with tendency to develop at time course was found. These disturbances are observed in the course of very good immunological stabilization and viral suppression. No unambiguous data and results of long term studies are available, that would confirm the increase of cardiovascular risk in HIV infected subjects. Nevertheless, this increase is required and anticipated.

Keywords: HIV; HAART; dyslipidaemia; cardiovascular risk

Received: August 13, 2007; Accepted: November 16, 2007; Published: February 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Snopková S, Povolná K, Husa P, Jarkovský J, Pavlík T. Dyslipidaemia inducted by antiretroviral agents. Vnitr Lek. 2008;54(2):169-177.
Download citation

References

  1. Staňková M, Skokanová V. Problematika HIV/AIDS - ohlédnutí a perspektivy. Klin mikrobiol inf lék 2004; 10: 56-60.
  2. 2005 Report on the global AIDS epidemic. UNAIDS 2006.
  3. Konvalinka J, Machala L. Terapie AIDS po dvaceti letech. Vesmír 2001; 6: 332-340.
  4. Hoffmann C, Rockstroh J, Kamps. S HIV Medicine 2006. 1st ed. Paris: Flying Publisher 2006.
  5. Carpentier A, Patterson BW, Uffelman KD et al. Mechanism of highly active antiretroviral therapy - induced hyperlipidemia in HIV-infected individuals. Atherosclerosis 2005; 178: 165-172. Go to original source... Go to PubMed...
  6. Barbaro G. Highly Active antiretroviral therapy and the cardiovascular system: the heart of the matter. Pharmacology 2003; 69: 177-179. Go to original source... Go to PubMed...
  7. Mary-Krause M, Cotte L, Simon A et al. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17: 2479-2486. Go to original source... Go to PubMed...
  8. Calza L, Manfredi R, Chiodo F. Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART. AIDS 2003; 17: 851-859. Go to original source... Go to PubMed...
  9. Broedl UC, Maugeais C, Millar JS et al. Endothelial lipase promotes the catabolism of ApoB-containing lipoproteins. Circ Res 2004; 94: 1554-1561. Go to original source... Go to PubMed...
  10. Reeds DN, Mittendorfer B, Patterson BW et al. Alterations in lipid kinetics in men with HIV-dyslipidemia. Am J Physiol 2003; 285: 490-497. Go to original source... Go to PubMed...
  11. Lichtenstein KA, Delaney KM, Armon C et al. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-infected patients. J Acquir Immune Defic Syndr 2003; 32: 48-56. Go to original source... Go to PubMed...
  12. Calza L, Manfredi R, Colangeli V et al. Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia. AIDS 2005; 19: 1051-1058. Go to original source... Go to PubMed...
  13. Herlihy OM, Barrow BA, Grant PJ et al. Hyperglycaemic siblings of Type II (non-insulin-dependent) diabetic patients have increased PAI-1, central obesity and insulin resistance compared with their paired normoglycaemic sibling. Diabetologia 2002; 45: 635-641. Go to original source... Go to PubMed...
  14. Hadigan C, Meigs JB, Corcoran C et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001; 32: 130-139. Go to original source... Go to PubMed...
  15. Addy CL, Gavrila A, Tsiodras S et al. Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. J Clin Endocrionol Metab 2003; 88: 627-636. Go to original source... Go to PubMed...
  16. Cotter BR. Endothelial dxsfunction in HIV infection. Curr HIV/AIDS Rep 2006; 3: 126-131. Go to original source... Go to PubMed...
  17. Mu H, Chai H, Lin PH et al. Current update on HIV-associated vascular disease and endothelial dysfunction. World J Surg 2007; 31: 632-643. Go to original source... Go to PubMed...
  18. Hurlimann D, Weber R, Enseleit F et al. HIV infection, antiretroviral therapy and endothelium. Herz 2005; 30: 472-480. Go to original source... Go to PubMed...
  19. Grinspoon SK. Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus. Am J Med 2005; 118: 23S-28S. Go to original source... Go to PubMed...
  20. Barbaro G. Highly active antiretroviral therapy-associated metabolic syndrome: pathogenesis and cardiovascular risk. Am J Ther 2006; 13: 248-260. Go to original source... Go to PubMed...
  21. Balasubramanyam A, Sekhar RV, Jahoor F et al. Pathophysiology of dyslipidemia and increased cardiovascular risk in HIV lipodystrophy: a model of "systemic steatosis". Curr Opin Lipidol 2004; 15: 59-67. Go to original source... Go to PubMed...
  22. Bartlett JG, Gallant JE. Medical management of HIV Infection 2004. Johns Hopkins University School of Medicine Baltimore, Health Publishing Business Group, 2004: 93-98.
  23. Nolan D. Metabolic complications associated with HIV protease inhibitor therapy. Drugs 2003; 63: 2555-2574. Go to original source... Go to PubMed...
  24. Perret B, Ferrand C, Bonnet E et al. Lipoprotein metabolism in HIV-positive patients. E J Med Res 2003; 8: Suppl. II: 6-7.
  25. De Gaetano Donati K, Rabagliati R, Iacoviello L et al. HIV infection, HAART, and endothelial adhesion molecules: current perspectives. Lancet Infect Dis 2004; 4: 213-222. Go to original source... Go to PubMed...
  26. Shahmanesh M, Das S, Stolinski M et al. Antiretroviral treatment reduces very-low-density lipoprotein and intermediate-density lipoprotein apolipoprotein B fractional catabolic rate in Human Immunodeficiency Virus-infected patients with mild dyslipidemia. J Clin Endocrinol Metab 2005; 2: 755-760. Go to original source... Go to PubMed...
  27. Calza L, Manfredi R, Chiodo F. Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART. AIDS 2003; 17: 851-859. Go to original source... Go to PubMed...
  28. The Writing Committee of the DAD Study Group. Cardio- and cerebrovascular events in HIV-infected persons. AIDS 2004; 13: 1811-1817 Go to original source... Go to PubMed...
  29. Soška V. Poruchy metabolizmu lipidů - diagnostika a léčba. Praha: Grada Publishing 2001.
  30. Soška V. Dyslipidemie u metabolického syndromu. Vnitř Lék 2005; 1: 77-81.
  31. Češka R. Jak dosáhnout cílových hodnot LDL-cholesterolu? Místo ezetimibu v moderní léčbě hypercholesterolemie. Cor Vasa 2004; 46: 452-456.
  32. Racek J et al. Klinická biochemie. Praha: Galén 2006.
  33. Frohlich J, Vrablík M. Apolipoprotein B v diagnostice a léčbě dyslipidemií. KF 2006; 4: 7-9.
  34. Barbado G. Pathogenesis of HIV-associated heart disease. AIDS 2003; 17: 12-20. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.